Equillium
Bruce is a co-founder, Director, and President and Chief Executive Officer of Equillium. He is also the founder and Managing Director of BioMed Ventures, the strategic investment arm of BioMed Realty. Since founding BioMed Ventures, Bruce has directed investments in over 30 biotechnology companies including Auspex, AnaptysBio, NeoTract and Receptos. Prior to co-founding Equillium, Bruce was co-founder and CEO of Rincon Pharmaceuticals, a genetic engineering biotechnology company, until its acquisition in 2008; previously he was Chief Business Officer at Anaphore and Head of Corporate Development at Ambit Biosciences. Bruce serves on the Board of Directors of Breathe Technologies and Aegea Medical, and is a board observer for a number of other private companies.
Bruce received his Bachelor of Arts degree from Dartmouth College and Master of Business Administration degree from the Marshall School of Business at the University of Southern California, and he holds the designation of Chartered Financial Analyst.
This person is not in any offices
Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs.